By Deborah Borfitz 

September 22, 2022 | Emerging approaches to the early detection of cancer, based on metabolic profiling and microbiome- and exosome-driven liquid biopsies, were highlighted during the recent Next Generation Dx Summit held in Washington, D.C. Representatives from diagnostics companies Oxomics, Elypta, Micronoma (University of California, San Diego, spinoff), and Rivela Diagnostics (an Exosomics company) took turns making their case for a new generation of technologies hunting for elusive molecular signatures of a highly heterogenous group of diseases. 

Read more at DiagnosticsWorld